# US 11,028,136 B2 · Tumor antigen peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,136 B2
- Document ID: US11028136B2
- Status: Granted
- Kind: B2
- Application number: 15/514,169
- Filed: 2015-09-24
- Published: 2017-10-19
- Granted: 2021-06-08
- Earliest claimed: 2014-09-24
- Assignees: Sapporo Medical University; Medical & Biological Laboratories Co., Ltd.
- Applicants: Sapporo Medical University; Medical & Biological Laboratories Co., Ltd.
- Inventors: Toshihiko Torigoe; Eri Atsuyama; Hironori Otaka; Kazue Nakano; Dongliang Li; Shingo Toji; Takuya Asano; Ryota Horibe; Yoshihiko Hirohashi; Noriyuki Sato; Tsuyoshi Saito
- Web page: https://patentgrep.com/patent/US11028136B2

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/18: against material from animals or humans
- C07K 16/30: from tumour cells
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/09: Recombinant DNA-technology
- G01N 33/57595: {involving intracellular compounds}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/572: {cytotoxic response}
- C07K 14/82: Translation products from oncogenes
- C12N 2510/00: Genetically modified cells
- G01N 2333/4704: Inhibitors; Supressors
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient. The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.

## Claims

### Claim 1

A method for inducing a cytotoxic T cell (CTL) that specifically recognizes a cell expressing a BORIS gene belonging to isoform A or C or a BORIS gene belonging to subfamily 5 or 6, the method comprising contacting in vitro:
(a) a polypeptide comprising the amino acids of SEQ ID NO: 3, SEQ ID NO: 10, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 or SEQ ID NO: 72, and having HLA-A11 antigen-binding capacity or HLA-A24 antigen-binding capacity, with a peripheral blood lymphocyte (PBL) expressing on the cell surface HLA-A11 antigen or HLA-A24 antigen,
(b) a polypeptide comprising the amino acids of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 47, or SEQ ID NO: 57, and having HLA-A2 antigen binding capacity, with a PBL expressing on the cell surface HLA-A2 antigen, or
(c) an expression vector encoding at least one of the polypeptides of (a) with the PBL expressing on the cell surface the HLA-A11 antigen or the HLA-A24 antigen or the polypeptide of (b) above with the PBL expressing on the cell surface the HLA-A2 antigen, wherein the sequence encoding the polypeptide of (a) or the polypeptide of (b) is operably linked to an expression control sequence:
wherein the polypeptide induces the CTL.

### Claim 2 (depends on 1)

The method according to claim 1, the polypeptide of (a) having the HLA-A11 antigen-binding capacity.

### Claim 3 (depends on 1)

The method according to claim 1, the polypeptide of (a) having the HLA-A24 antigen-binding capacity.

### Claim 4 (depends on 1)

The method according to claim 1, the step of contacting in vitro further comprising pulsing the PBL with the polypeptide.

### Claim 5 (depends on 1)

The method according to claim 1, the method further comprising intravenous, subcutaneous or intradermal administration of a pharmaceutical composition containing as an active ingredient the CTL to a patient having a cancer that is positive for the BORIS gene belonging to the isoform A or C or the BORIS gene belonging to the subfamily 5 or 6, wherein the PBL is obtained from the patient.

### Claim 6

A method of treating a lung cancer or a female reproductive organ cancer comprising intravenously or subcutaneously administering to a subject with the lung cancer or the female reproductive organ cancer:
(a) a polypeptide comprising the amino acids of SEQ ID NO: 3, SEQ ID NO: 10, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 or SEQ ID NO: 72 and having HLA-A11 antigen-binding capacity or HLA-A24 antigen-binding capacity, or
(b) a polypeptide comprising the amino acids of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 47, or SEQ ID NO: 57, and having HLA-A2 antigen binding capacity,
wherein the administered polypeptide induces CTL upon contact with PBLs in the subject expressing on the cell surface the HLA-A11 antigen or the HLA-A24 antigen or the polypeptide of (b) with the PBLs expressing on the cell surface the HLA-A2 antigen,
wherein the lung cancer or the cancer in a female specific reproductive organ cancer expresses a BORIS gene belonging to isoform A or C or a BORIS gene belonging to subfamily 5 or 6,
wherein the subject administered the polypeptide of (a) is the HLA-A11 antigen positive or the HLA-A24 antigen positive, or the subject administered the polypeptide of (b) is the HLA-A2 antigen positive, and
wherein the CTL induction treats the lung cancer or the female reproductive organ cancer.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the lung cancer or the female reproductive organ cancer comprises a cancer stem cell.